{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:46:22Z","timestamp":1761896782441},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/cvr\/cvy144","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T11:07:58Z","timestamp":1528456078000},"page":"1595-1604","source":"Crossref","is-referenced-by-count":10,"title":["Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?"],"prefix":"10.1093","volume":"114","author":[{"given":"Davide","family":"Noto","sequence":"first","affiliation":[{"name":"Department of Bioscience Internal Medicine and Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonina","family":"Giammanco","sequence":"additional","affiliation":[{"name":"Department of Bioscience Internal Medicine and Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo M","family":"Barbagallo","sequence":"additional","affiliation":[{"name":"Department of Bioscience Internal Medicine and Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo B","family":"Cefal\u00f9","sequence":"additional","affiliation":[{"name":"Department of Bioscience Internal Medicine and Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio R","family":"Averna","sequence":"additional","affiliation":[{"name":"Department of Bioscience Internal Medicine and Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"key\n\t\t\t\t20180921045208_cvy144-B1","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","article-title":"Molecular diagnosis of hypobetalipoproteinemia: an ENID review","volume":"195","author":"Tarugi","year":"2007","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","article-title":"Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials","volume":"178","author":"Ridker","year":"2016","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B3","author":"EMA, Evolocumab"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B4","author":"EMA, Evolocumab"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B5","doi-asserted-by":"crossref","first-page":"21473","DOI":"10.1074\/jbc.R113.481549","article-title":"The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions","volume":"288","author":"Seidah","year":"2013","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B7","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvw194","article-title":"Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering","volume":"112","author":"Norata","year":"2016","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/bcp.13066","article-title":"Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia","volume":"82","author":"Gouni-Berthold","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00592-016-0931-4","article-title":"Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature","volume":"54","author":"Noto","year":"2017","journal-title":"Acta Diabetol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B11","doi-asserted-by":"crossref","first-page":"24270","DOI":"10.1074\/jbc.M702442200","article-title":"Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia","volume":"282","author":"Burnett","year":"2007","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2009.01.037","article-title":"Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia","volume":"206","author":"Noto","year":"2009","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B13","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1161\/ATVBAHA.112.301101","article-title":"A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia","volume":"33","author":"Cefal\u00f9","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2010.03.039","article-title":"Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia","volume":"139","author":"Amaro","year":"2010","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2265.2012.04498.x","article-title":"Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology","volume":"79","author":"Della Corte","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B16","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1161\/01.ATV.18.8.1330","article-title":"A truncated species of apolipoprotein B (B-38.7) in a patient with homozygous hypobetalipoproteinemia associated with diabetes mellitus","volume":"18","author":"Ohashi","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B17","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/ATVBAHA.111.238766","article-title":"Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia","volume":"32","author":"Noto","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B19","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"ANGPTL3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbalip.2011.10.010","article-title":"Regulation of triglyceride metabolism by Angiopoietin-like proteins","volume":"1821","author":"Mattijssen","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B21","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1073\/pnas.1217552109","article-title":"Atypical angiopoietin-like protein that regulates ANGPTL3","volume":"109","author":"Quagliarini","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B22","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1210\/en.2005-0476","article-title":"Transgenic angiopoietin-like (ANGPTL)4 overexpression and targeted disruption of ANGPTL4 and ANGPTL3: regulation of triglyceride metabolism","volume":"146","author":"K\u00f6ster","year":"2005","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B24","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.ATV.0000255311.26383.2f","article-title":"A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol","volume":"27","author":"Fasano","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B28","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B31","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.M200342-JLR200","article-title":"Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis","volume":"44","author":"Schonfeld","year":"2003","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2014.02.014","article-title":"Statin treatment and new-onset diabetes: a review of proposed mechanisms","volume":"63","author":"Brault","year":"2014","journal-title":"Metabolism"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(14)70002-9","article-title":"Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin","volume":"16","author":"Arnaboldi","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"Jama"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"Jama"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B42","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00125-015-3659-8","article-title":". The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis","volume":"58","author":"Bonnefond","year":"2015","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B43","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B45","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/dc17-1464","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years","volume":"41","author":"de Carvalho","year":"2018","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B47","doi-asserted-by":"crossref","first-page":"1391.","DOI":"10.1111\/dom.13235","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis","volume":"20","author":"Cao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B48","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B49","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/ATVBAHA.116.307995","article-title":"Carriers of the PCSK9 R46L variant are characterized by an antiatherogenic lipoprotein profile assessed by nuclear magnetic resonance spectroscopy-brief report","volume":"37","author":"Verbeek","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.mp.4001910","article-title":"Violent behavior associated with hypocholesterolemia due to a novel APOB gene mutation","volume":"12","author":"Edgar","year":"2007","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B52","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1073\/pnas.90.6.2389","article-title":"Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice","volume":"90","author":"Homanics","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B53","first-page":"1468","article-title":"Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene","volume":"101","author":"Kim","year":"1998","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.atherosclerosis.2015.01.014","article-title":"Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature","volume":"239","author":"Cefal\u00f9","year":"2015","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B55","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.116.025233","article-title":"Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies","volume":"135","author":"Toth","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B56","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","article-title":"Safety of alirocumab (A PCSK9 monoclonal antibody) from 14 randomized trials","volume":"118","author":"Jones","year":"2016","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B59","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.2337\/db07-0056","article-title":"Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction","volume":"56","author":"Hao","year":"2007","journal-title":"Diabetes"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B60","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","article-title":"Cholesterol metabolism and homeostasis in the brain","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"key\n\t\t\t\t20180921045208_cvy144-B61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.plipres.2011.06.002","article-title":"Cholesterol metabolism in neurons and astrocytes","volume":"50","author":"Pfrieger","year":"2011","journal-title":"Prog Lipid Res"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/114\/12\/1595\/25811607\/cvy144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T06:51:08Z","timestamp":1571467868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/114\/12\/1595\/5040492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,6,20]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvy144","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,1]]},"published":{"date-parts":[[2018,6,20]]}}}